Shattuck Labs, Inc. (STTK)
After hours:
| Previous close | 9.49 |
| Open | 9.41 |
| Bid | 9.84 x 100 |
| Ask | 9.92 x 200 |
| Day's range | 9.41 - 10.08 |
| 52-week range | 1.33 - 11.11 |
| Volume | |
| Avg. volume | 328,637 |
| Market cap | 470.001M |
| Beta (5Y monthly) | 2.13 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.05 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 15.75 |
Simply Wall St.Owning 36% shares,institutional owners seem interested in Shattuck Labs, Inc. (NASDAQ:STTK),
Key Insights Significantly high institutional ownership implies Shattuck Labs' stock price is sensitive to their...
GlobeNewswireShattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
– Aberrant TRIM7 expression identified as a key driver of immune checkpoint blockade (ICB) acquired resistance; inhibition of TRIM7 with small molecule inhibitors may prevent or reverse acquired resistance to PD-1/L1 blockade – AUSTIN, TX and DURHAM, NC, April 09, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients
- GlobeNewswire
Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference
AUSTIN, TX & DURHAM, NC, April 01, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in the 23rd Annual Needham Virtual Healthcare Conference being held virtually from April 8-11, 2024. Presentation DetailsConference: 23
